Fig 1.
Study disposition and main outcomes.
Table 1.
Clinical characteristics of patients in both groups.
N.S.: Non significant.
Fig 2.
A. Levels of IgA anti B2GP1 and IgG and IgM anticardiolipin antibodies in Group-1 (grey) and in Group-2 (white). Dotted line corresponds to the cut-off. B. Accumulation of events as a function of time (p<0.001) in group 1 (red) and Group-2 (blue). Dotted lines represent trends.
Table 2.
APS events during the five years of the follow-up.
N.S.: Non significant.
Table 3.
Characteristics of the patients who suffer an APS event during the follow up versus patients without APS events.
N.S.: Non significant.
Table 4.
Multivariate análisis to APS-events associated-factors.
A. Model with the five most significant variables (selection criteria p<0.01). B. Model replacing the previous model less-significant variable (hypertension) by dyslipidemia. C. Model with the three significant variables in the previous models.
Table 5.
Rapid calculation of the risk to undergo a first APS event in the next 5 years of a previously symptomatic patient.
The risk is based on the values of the three main risk factors. Moderate risk is marked in orange. high risk in red and very high risk in violet. The values in yellow are close to the cut-off point (10.6).
Table 6.
Study for validate aCL antibodies (IgG and IgM) as screening to identify patients positive for aPL consensus (aCL and aB2GP1 IgG/IgM).